Refine
Has Fulltext
- yes (35)
Is part of the Bibliography
- yes (35)
Year of publication
- 2016 (35) (remove)
Document Type
- Journal article (35) (remove)
Language
- English (35)
Keywords
- Aspergillus fumigatus (2)
- Bone-marrow-transplantation (2)
- chemotherapy (2)
- multiple myeloma (2)
- 177Lu (1)
- AIDS (1)
- Acute lymphocytic leukaemia (1)
- Alpha therapy (1)
- Autoimmune diseases (1)
- Bacteria (1)
- Bone marrow transplantantation (1)
- Breath tests (1)
- CA19-9 (1)
- CD11b+ myeloid cells (1)
- Cancer genetics (1)
- Candida albicans (1)
- Central nervous system (1)
- Central nervous system infection (1)
- Clinical practice guidelines (1)
- Clinical remission (1)
- Cytokine receptors (1)
- Diagnosis (1)
- Drug development (1)
- Drug metabolism (1)
- Drug-free remission (1)
- Duchenne muscular dystrophy (1)
- Expression (1)
- FOLFIRI (1)
- FOLFOX (1)
- Factor receptor (1)
- Fungal (1)
- Genetics research (1)
- Glucose metabolism (1)
- Graft versus Tumor (1)
- Graft-versus-leukemia (1)
- Guideline (1)
- Guinea pig model (1)
- HIV (1)
- HIV infections (1)
- Hepatitis B virus (1)
- Hepatitis C (1)
- Herpes simplex encephalitis (1)
- Herpes simplex virus (1)
- Hsp90 (1)
- Human immunodefiency virus (1)
- IL-12 family (1)
- Imatinib (1)
- Immunocompromised patient (1)
- Infections (1)
- Inflammation (1)
- Influenzae type B (1)
- Intracellular domain (1)
- Invasive Aspergillosis (1)
- Invasive fungal-infections (1)
- Jak kinases (1)
- Lipid metabolism (1)
- Liposomal amphotericin-B (1)
- Liver cirrhosis (1)
- Low-dose acyclovir (1)
- MAG3 (1)
- MPACT (1)
- Malignant melanoma (1)
- NFkB-relatedgenes (1)
- PRRT (1)
- Pneumocystis-carinii-pneumonia (1)
- Polymerase chain raction (1)
- Progressive multifocal leukoencephalopathy (1)
- Real-time PCR (1)
- Regulatory-cells (1)
- Respiratory syncytial virus (1)
- Responses (1)
- Rheumatoid arthritis (1)
- STAT3 activation (1)
- Signal transduction (1)
- Skin cancer screening (1)
- Stage distribution (1)
- Suppression (1)
- Survival analysis (1)
- Synovitis (1)
- T-cells (1)
- TNM staging (1)
- Th17 (1)
- Transport (1)
- Treatment (1)
- Tregs (1)
- Tumor-necrosis-factor (1)
- Tyrosine phosphorylation (1)
- Validation (1)
- Varicella-Zoster-Virus (1)
- Varicella-zoster-virus (1)
- Viral (1)
- acute Graft versus Host Disease (1)
- adenocarcinoma of the ampulla of Vater (1)
- adjuvant (1)
- allogeneic stem cell transplantation (1)
- alternative to animal testing (1)
- amphotericin B (1)
- amplicon sequencing (1)
- anaplastic medulloblastoma (1)
- anastomotic leakage (1)
- anemia (1)
- animal model (1)
- antiviral treatment (1)
- aspergillus fumigatus (1)
- beta-D-glucan (1)
- biliary-tract cancer (1)
- biomarkers Myelomas (1)
- blood flow (1)
- bone imaging (1)
- brain tumor (1)
- cancer stem cells (1)
- care (1)
- children (1)
- chronic myelogenous leukemia (1)
- clinical-practice (1)
- collagens (1)
- complication (1)
- corticosteroids and cyclophosphamide (1)
- daratumumab monotherapy (1)
- discordance (1)
- disease-activity score (1)
- drug adherence (1)
- endosponge (1)
- epithelial-mesenchymal transition (1)
- european leukemia net (1)
- fatigue (1)
- fatty liver (1)
- fine-needle-aspiration (1)
- fluorescence microscopy (1)
- fluorescent dyes (1)
- fungal disease (1)
- fungal host response (1)
- fungal infection (1)
- galactomannan (1)
- gastric cancer (1)
- gastrointestinal dysfunction (1)
- gemcitabine (1)
- gene expression data (1)
- gene regulation in immune cells (1)
- genetic polymorphisms (1)
- group 3 (1)
- growth-factor-receptor (1)
- health-assessment questionnaire (1)
- hematopoietic SCT (1)
- hepatic stellate cells (1)
- high-risk hematology (1)
- highly-active antiretroviral therapy (1)
- human biomarker (1)
- human cholangiocellular carcinoma (1)
- human intrahepatic cholangiocarcinoma (1)
- immune activation (1)
- immune cell recruitment (1)
- induce cyclooxygenase-2 expression (1)
- insulin (1)
- insulin signaling (1)
- integrins (1)
- interaction (1)
- interferon alpha (IFNα) (1)
- interferon alpha signalling (1)
- interferon-alpha (1)
- intestinal-type adenocarcinoma (1)
- invasive aspergillosis (1)
- invasive fungal infections (1)
- ischemic stroke (1)
- leukemia (1)
- mammalian genomics (1)
- melanoma therapy (1)
- methylation (1)
- micronuclei (1)
- minimally important difference (1)
- molecular response in cml (1)
- mouse models DNA damage (1)
- multimodal (1)
- multiple myeloma Lesions (1)
- myeloma cells (1)
- nab-paclitaxel (1)
- nanoparticle albumin-bound paclitaxel (1)
- neoadjuvant (1)
- neuroendocrine tumor (1)
- nucleoside transporter (1)
- oncology (1)
- orthotopic xenograft (1)
- oxidative stress (1)
- pancreatic cancer (1)
- pancreatobiliary type (1)
- panobinostat (1)
- physicians (1)
- platelet activation (1)
- platelet aggregation (1)
- platelets (1)
- primary sclerosing cholangitis (1)
- pulmonary aspergillosis (1)
- rare SNP (1)
- real-time PCR (1)
- receptor tyrosine kinases (1)
- relapsed (1)
- relapsed and refractory (1)
- renal scintigraphy (1)
- reported outcomes (1)
- ribavirin serum levels (1)
- risk factor (1)
- serotonin (1)
- skin equivalents (1)
- suppression (1)
- survival (1)
- susceptibility (1)
- systemic sclerosis (1)
- tissue engineering (1)
- transporter protein associated with antigen processing-1 (TAP1) (1)
- validation (1)
- vascularization (1)
- viral load (1)
- viral replication (1)
Institute
- Medizinische Klinik und Poliklinik II (35) (remove)
Background: There is much evidence that T cells are strongly involved in the pathogenesis of localized and systemic forms of scleroderma (SSc). A dysbalance between FoxP3+ regulatory CD4+ T cells (Tregs) and inflammatory T-helper (Th) 17 cells has been suggested. Methods: The study aimed (1) to investigate the phenotypical and functional characteristics of Th17 and Tregs in SSc patients depending on disease manifestation (limited vs. diffuse cutaneous SSc, dcSSc) and activity, and (2) the transcriptional level and methylation status of Th17- and Treg-specific transcription factors. Results: There was a concurrent accumulation of circulating peripheral IL-17-producing CCR6+ Th cells and FoxP3+ Tregs in patients with dcSSc. At the transcriptional level, Th17- and Treg-associated transcription factors were elevated in SSc. A strong association with high circulating Th17 and Tregs was seen with early, active, and severe disease presentation. However, a diminished suppressive function on autologous lymphocytes was found in SSc-derived Tregs. Significant relative hypermethylation was seen at the gene level for RORC1 and RORC2 in SSc, particularly in patients with high inflammatory activity. Conclusions: Besides the high transcriptional activity of T cells, attributed to Treg or Th17 phenotype, in active SSc disease, Tregs may be insufficient to produce high amounts of IL-10 or to control proliferative activity of effector T cells in SSc. Our results suggest a high plasticity of Tregs strongly associated with the Th17 phenotype. Future directions may focus on enhancing Treg functions and stabilization of the Treg phenotype.
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of biliary tract differentiation. CCA is the second most common primary liver tumour and the incidence is increasing worldwide. CCA has high mortality owing to its aggressiveness, late diagnosis and refractory nature. In May 2015, the "European Network for the Study of Cholangiocarcinoma" (ENS-CCA: www.enscca.org or www.cholangiocarcinoma.eu) was created to promote and boost international research collaboration on the study of CCA at basic, translational and clinical level. In this Consensus Statement, we aim to provide valuable information on classifications, pathological features, risk factors, cells of origin, genetic and epigenetic modifications and current therapies available for this cancer. Moreover, future directions on basic and clinical investigations and plans for the ENS-CCA are highlighted.
Role of PTEN in Oxidative Stress and DNA Damage in the Liver of Whole-Body Pten Haplodeficient Mice
(2016)
Type 2 diabetes (T2DM) and obesity are frequently associated with non-alcoholic fatty liver disease (NAFLD) and with an elevated cancer incidence. The molecular mechanisms of carcinogenesis in this context are only partially understood. High blood insulin levels are typical in early T2DM and excessive insulin can cause elevated reactive oxygen species (ROS) production and genomic instability. ROS are important for various cellular functions in signaling and host defense. However, elevated ROS formation is thought to be involved in cancer induction. In the molecular events from insulin receptor binding to genomic damage, some signaling steps have been identified, pointing at the PI3K/AKT pathway. For further elucidation Phosphatase and Tensin homolog (Pten), a tumour suppressor phosphatase that plays a role in insulin signaling by negative regulation of PI3K/AKT and its downstream targets, was investigated here. Dihydroethidium (DHE) staining was used to detect ROS formation in immortalized human hepatocytes. Comet assay and micronucleus test were performed to investigate genomic damage in vitro. In liver samples, DHE staining and western blot detection of HSP70 and HO-1 were performed to evaluate oxidative stress response. DNA double strand breaks (DSBs) were detected by immunohistostaining. Inhibition of PTEN with the pharmacologic inhibitor VO-OHpic resulted in increased ROS production and genomic damage in a liver cell line. Knockdown of Pten in a mouse model yielded increased oxidative stress levels, detected by ROS levels and expression of the two stress-proteins HSP70 and HO-1 and elevated genomic damage in the liver, which was significant in mice fed with a high fat diet. We conclude that PTEN is involved in oxidative stress and genomic damage induction in vitro and that this may also explain the in vivo observations. This further supports the hypothesis that the PI3K/AKT pathway is responsible for damaging effects of high levels of insulin.
Hsp90 inhibition ameliorates CD4\(^{+}\) T cell-mediated acute Graft versus Host disease in mice
(2016)
Introduction:
For many patients with leukemia only allogeneic bone marrow transplantion provides a chance of cure. Co‐transplanted mature donor T cells mediate the desired Graft versus Tumor (GvT) effect required to destroy residual leukemic cells. The donor T cells very often, however, also attack healthy tissue of the patient inducing acute Graft versus Host Disease (aGvHD)—a potentially life‐threatening complication.
Methods:
Therefore, we used the well established C57BL/6 into BALB/c mouse aGvHD model to evaluate whether pharmacological inhibition of heat shock protein 90 (Hsp90) would protect the mice from aGvHD.
Results:
Treatment of the BALB/c recipient mice from day 0 to +2 after allogeneic CD4\(^{+}\) T cell transplantation with the Hsp90 inhibitor 17‐(dimethylaminoethylamino)‐17‐demethoxygeldanamycin (DMAG) partially protected the mice from aGvHD. DMAG treatment was, however, insufficient to prolong overall survival of leukemia‐bearing mice after transplantation of allogeneic CD4\(^{+}\) and CD8\(^{+}\) T cells. Ex vivo analyses and in vitro experiments revealed that DMAG primarily inhibits conventional CD4\(^{+}\) T cells with a relative resistance of CD4\(^{+}\) regulatory and CD8\(^{+}\) T cells toward Hsp90 inhibition.
Conclusions:
Our data, thus, suggest that Hsp90 inhibition might constitute a novel approach to reduce aGvHD in patients without abrogating the desired GvT effect.
Background
A phase I/II study and subsequent phase III study (MPACT) reported significant correlations between CA19-9 decreases and prolonged overall survival (OS) with nab-paclitaxel plus gemcitabine (nab-P + Gem) treatment for metastatic pancreatic cancer (MPC). CA19-9 changes at week 8 and potential associations with efficacy were investigated as part of an exploratory analysis in the MPACT trial.
Patients and methods
Untreated patients with MPC (N = 861) received nab-P + Gem or Gem alone. CA19-9 was evaluated at baseline and every 8 weeks.
Results
Patients with baseline and week-8 CA19-9 measurements were analyzed (nab-P + Gem: 252; Gem: 202). In an analysis pooling the treatments, patients with any CA19-9 decline (80%) versus those without (20%) had improved OS (median 11.1 versus 8.0 months; P = 0.005). In the nab-P + Gem arm, patients with (n = 206) versus without (n = 46) any CA19-9 decrease at week 8 had a confirmed overall response rate (ORR) of 40% versus 13%, and a median OS of 13.2 versus 8.3 months (P = 0.001), respectively. In the Gem-alone arm, patients with (n = 159) versus without (n = 43) CA19-9 decrease at week 8 had a confirmed ORR of 15% versus 5%, and a median OS of 9.4 versus 7.1 months (P = 0.404), respectively. In the nab-P + Gem and Gem-alone arms, by week 8, 16% (40/252) and 6% (13/202) of patients, respectively, had an unconfirmed radiologic response (median OS 13.7 and 14.7 months, respectively), and 79% and 84% of patients, respectively, had stable disease (SD) (median OS 11.1 and 9 months, respectively). Patients with SD and any CA19-9 decrease (158/199 and 133/170) had a median OS of 13.2 and 9.4 months, respectively.
Conclusion
This analysis demonstrated that, in patients with MPC, any CA19-9 decrease at week 8 can be an early marker for chemotherapy efficacy, including in those patients with SD. CA19-9 decrease identified more patients with survival benefit than radiologic response by week 8.
Donor CD4\(^+\)Foxp3\(^+\) regulatory T cells (T reg cells) suppress graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HCT allo-HCT]). Current clinical study protocols rely on the ex vivo expansion of donor T reg cells and their infusion in high numbers. In this study, we present a novel strategy for inhibiting GvHD that is based on the in vivo expansion of recipient T reg cells before allo-HCT, exploiting the crucial role of tumor necrosis factor receptor 2 (TNFR2) in T reg cell biology. Expanding radiation-resistant host T reg cells in recipient mice using a mouse TNFR2-selective agonist before allo-HCT significantly prolonged survival and reduced GvHD severity in a TNFR2-and T reg cell-dependent manner. The beneficial effects of transplanted T cells against leukemia cells and infectious pathogens remained unaffected. A corresponding human TNFR2-specific agonist expanded human T reg cells in vitro. These observations indicate the potential of our strategy to protect allo-HCT patients from acute GvHD by expanding T reg cells via selective TNFR2 activation in vivo.
Invasive fungal infections are associated with high mortality rates and are mostly caused by the opportunistic fungi Aspergillus fumigatus and Candida albicans. Immune responses against these fungi are still not fully understood. Dendritic cells (DCs) are crucial players in initiating innate and adaptive immune responses against fungal infections. The immunomodulatory effects of fungi were compared to the bacterial stimulus LPS to determine key players in the immune response to fungal infections. A genome wide study of the gene regulation of human monocyte-derived dendritic cells (DCs) confronted with A. fumigatus, C. albicans or LPS was performed and Krüppel-like factor 4 (KLF4) was identified as the only transcription factor that was down-regulated in DCs by both fungi but induced by stimulation with LPS. Downstream analysis demonstrated the influence of KLF4 on the interleukine-6 expression in human DCs. Furthermore, KLF4 regulation was shown to be dependent on pattern recognition receptor ligation. Therefore KLF4 was identified as a controlling element in the IL-6 immune response with a unique expression pattern comparing fungal and LPS stimulation.
Background
Medulloblastoma is the most common malignant brain tumor in children and can be divided in different molecular subgroups. Patients whose tumor is classified as a Group 3 tumor have a dismal prognosis. However only very few tumor models are available for this subgroup.
Methods
We established a robust orthotopic xenograft model with a cell line derived from the malignant pleural effusions of a child suffering from a Group 3 medulloblastoma.
Results
Besides classical characteristics of this tumor subgroup, the cells display cancer stem cell characteristics including neurosphere formation, multilineage differentiation, CD133/CD15 expression, high ALDH-activity and high tumorigenicity in immunocompromised mice with xenografts exactly recapitulating the original tumor architecture.
Conclusions
This model using unmanipulated, human medulloblastoma cells will enable translational research, specifically focused on Group 3 medulloblastoma.
Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance
(2016)
Liver cirrhosis is the common endpoint of many hepatic diseases and represents a relevant risk for liver failure and hepatocellular carcinoma. The progress of liver fibrosis and cirrhosis is accompanied by deteriorating liver function. This review summarizes the regulatory and functional changes in phase I and phase II metabolic enzymes as well as transport proteins and provides an overview regarding lipid and glucose metabolism in cirrhotic patients. Interestingly, phase I enzymes are generally downregulated transcriptionally, while phase II enzymes are mostly preserved transcriptionally but are reduced in their function. Transport proteins are regulated in a specific way that resembles the molecular changes observed in obstructive cholestasis. Lipid and glucose metabolism are characterized by insulin resistance and catabolism, leading to the disturbance of energy expenditure and wasting. Possible non-invasive tests, especially breath tests, for components of liver metabolism are discussed. The heterogeneity and complexity of changes in hepatic metabolism complicate the assessment of liver function in individual patients. Additionally, studies in humans are rare, and species differences preclude the transferability of data from rodents to humans. In clinical practice, some established global scores or criteria form the basis for the functional evaluation of patients with liver cirrhosis, but difficult treatment decisions such as selection for transplantation or resection require further research regarding the application of existing non-invasive tests and the development of more specific tests.
Invasive aspergillosis (IA) is a devastating opportunistic infection and its treatment constitutes a considerable burden for the health care system. Immunocompromised patients are at an increased risk for IA, which is mainly caused by the species Aspergillus fumigatus. An early and reliable diagnosis is required to initiate the appropriate antifungal therapy. However, diagnostic sensitivity and accuracy still needs to be improved, which can be achieved at least partly by the definition of new biomarkers. Besides the direct detection of the pathogen by the current diagnostic methods, the analysis of the host response is a promising strategy toward this aim. Following this approach, we sought to identify new biomarkers for IA. For this purpose, we analyzed gene expression profiles of hematological patients and compared profiles of patients suffering from IA with non-IA patients. Based on microarray data, we applied a comprehensive feature selection using a random forest classifier. We identified the transcript coding for the S100 calcium-binding protein B (S100B) as a potential new biomarker for the diagnosis of IA. Considering the expression of this gene, we were able to classify samples from patients with IA with 82.3% sensitivity and 74.6% specificity. Moreover, we validated the expression of S100B in a real-time reverse transcription polymerase chain reaction (RT-PCR) assay and we also found a down-regulation of S100B in A. fumigatus stimulated DCs. An influence on the IL1B and CXCL1 downstream levels was demonstrated by this S100B knockdown. In conclusion, this study covers an effective feature selection revealing a key regulator of the human immune response during IA. S100B may represent an additional diagnostic marker that in combination with the established techniques may improve the accuracy of IA diagnosis.